Some time back I was reading about John Mckeen who went on to become CEO of world's largest Pharmaceutical company "Pfizer (NYSE-PFE)", Mckeen once said "idle money was a non-productive sin" and to make more money regardless of business line and till now Pfizer has displayed this pure pragmatic approach of making profits with mergers and acquisition ......and next to follow its path is GlaxoSmithKline (NYSE-GSK)....
After Pfizer’s $68 Billion deal to acquire Wyeth, then long time waited acquisition of Schering-Plough Corp by Merck & Co for $41.1 billion came along..... In queue was GlaxoSmithKline and GSK yesterday announced that it will acquire Stiefel for a cash consideration of $2.9 billion. A potential $0.3 billion cash payment will be there on future performance.
In the coming decades likewise AIDS drug collaboration between Pfizer and GSK, we may expect collaboration of these two giants to capture the overall derma segment of world :)
No comments:
Post a Comment